Genotyping News and Research

RSS

Asuragen reports collaborative study results of advanced PCR-based molecular profiling of FMR1 gene

Asuragen, Inc. announced today the results from two collaborative studies, one with the University of California Davis M.I.N.D. Institute and another with Rush University Medical Center, that demonstrate comprehensive molecular profiling of the Fragile X Mental Retardation (FMR1) gene using advanced PCR-based methods.

26 Jul 2010

Affymetrix second-quarter total revenue decreases to $71.7 million

Affymetrix, Inc., today reported its operating results for the second quarter of 2010. Total revenue for the quarter was $71.7 million, in line with previously announced expectations, as compared to total revenue of $81.6 million in the second quarter of 2009.

22 Jul 2010

INRA Genomic Platform core facility now provides services on Fluidigm's BioMark System for Genetic Analysis

Fluidigm Corporation today announced that the Toulouse Midi-Pyrénées Genomic Platform - Genotoul INRA core facility is now providing a wide range of services on a BioMark™ System for Genetic Analysis to a wide range of French researchers. These services include SNP genotyping, gene expression analysis and digital PCR quantification of DNA libraries for next-generation sequencing. The INRA has been validating the performance of the system on several projects over the past year.

21 Jul 2010

Affymetrix introduces Axiom Custom Genotyping Arrays

Affymetrix, Inc. today announced that it has launched Axiom™ Custom Genotyping Arrays, the newest addition to the Axiom Genotyping Solution. Researchers can now leverage Affymetrix' Axiom Genomic Database, the world's largest collection of validated common and rare SNPs, to create custom arrays containing 50,000 to as many as 2.6 million SNPs. This inherent flexibility allows researchers to conduct genome-wide association, replication, fine mapping, and candidate gene studies on a single platform.

21 Jul 2010

SeqWright congratulates EraGen on successful FDA 510(k) market clearance of MultiCode-RTx HSV 1 & 2 Kit

EraGen Biosciences Inc., Madison, Wis., was congratulated today by SeqWright, Inc., Houston, on EraGen's successful FDA 510(k) market clearance of its MultiCode-RTx HSV 1 & 2 Kit. This new kit is the first FDA-cleared PCR-based qualitative in vitro diagnostic test for the detection and typing of HSV-1 and HSV-2 from vaginal lesion swab specimens in symptomatic female patients.

13 Jul 2010

Screening for HPV genotypes 16 and 18 helps detect cervical pre-cancer missed by Pap test

Roche today announced that data from the ATHENA (Addressing THE Need for Advanced HPV Diagnostics) U.S. registration trial of over 47,000 women demonstrate that two human papillomavirus genotypes, HPV 16 and HPV 18, can identify those women with cervical pre-cancer missed by cytologic examination with a Papanicolau (Pap) test.

From Roche Sequencing and Life Science 9 Jul 2010

QIAGEN receives CE conformity marking for careHPV Test

QIAGEN has completed European certification of its careHPV™ Test to bring human papillomavirus (HPV) testing to public-health programs in low-resource, developing countries, the company announced today at the International Papillomavirus Conference in Montreal, Canada. The CE conformity marking ("Conformite Europeenne") certifies that the careHPV Test has met European Union consumer safety and health requirements, allowing the test to be distributed in developing countries that recognize the CE mark.

From QIAGEN Manchester Limited 7 Jul 2010

BIDMC calls for new training program for personalized healthcare

The Department of Pathology at Beth Israel Deaconess Medical Center (BIDMC) have issued "A Call to Action" for the medical profession to catch up with the technology and business communities in the application of genomics to personalized health care.

2 Jul 2010

SAIC-Frederick, Fluidigm collaborate to decode entire genome of Epstein-Barr virus

SAIC-Frederick, Inc. and Fluidigm Corporation are collaborating to decode the entire genome of the Epstein-Barr virus (EBV) using technology that can speed up research on the genetic basis of cancer and other diseases.

1 Jul 2010

Gene diagnosis to be featured at 9th INT'L BIO FORUM & BIO EXPO JAPAN

9th INT'L BIO FORUM & BIO EXPO JAPAN, organized by Reed Exhibitions Japan, will come back again as Asia's largest bio-event from June 30 - July 2, 2010. "Gene diagnosis" is one of the featured topics for this year.

30 Jun 2010

9th INT'L BIO FORUM & BIO EXPO JAPAN from June 30 - July 2, 2010

18 Jun 2010

Applied BioCode's novel BMB technology to be presented at Biodetection Technologies 2010 Conference

Applied BioCode, Inc. announced today a presentation to be given on their Barcoded Magnetic Beads technology at the Biodetection Technologies 2010 Conference in Arlington, Virginia. The presentation is titled "Multiplexed Assays Go Digital" and will be given by Dr. Winston Ho, President at Applied BioCode, on June 18, 2010.

18 Jun 2010

New genetic discoveries from Autism Genome Project

An international consortium of researchers working under the auspices of Autism Speaks, the world's largest autism science and advocacy organization, has announced new genetic discoveries from the second phase of its collaborative study: the Autism Genome Project. The results were published today in the journal Nature, one of the world's most respected peer-reviewed scientific publications.

10 Jun 2010

Fluidigm develops world's first reusable bio-chip architecture

Fluidigm Corporation today announced it has developed the world's first reusable bio-chip architecture for the commercial market. These reusable integrated fluidic circuits (IFCs) will dramatically lower SNP genotyping costs and are designed to support accelerated sample throughput, while maintaining data quality of 99.75 percent or greater accuracy and 99 percent or greater call rates.

9 Jun 2010

Infinity announces Phase 2 clinical trial results of IPI-504 for NSCLC

Infinity Pharmaceuticals, Inc. today reported the results from its Phase 2 clinical trial of IPI-504, the company's i.v.-administered Hsp90 chaperone inhibitor, in patients with advanced non-small cell lung cancer (NSCLC). Data reported show that IPI-504 demonstrated clinical activity in patients with NSCLC, in particular among patients with oncogenic anaplastic lymphoma kinase (ALK) gene rearrangements.

4 Jun 2010

New pricing of $19,500 set for Illumina's individual genome sequencing service

Illumina, Inc. today announced a new price of $19,500 for its individual genome sequencing service. In addition, the company announced a price of $14,500 per genome for groups of five or more participants using the same physician. Individuals with serious medical conditions for whom whole-genome sequencing could provide potential direct clinical value will be eligible for special pricing of $9,500 per genome.

From Illumina, Inc. 4 Jun 2010

Scientists awarded $3.9M grant to study how XDR-TB transmitted in rural South Africa

The National Institutes of Health has awarded scientists at Albert Einstein College of Medicine of Yeshiva University a five-year, $3.9 million grant to study how extensively drug-resistant tuberculosis is transmitted in rural South Africa. The findings could alter public health approaches for controlling the XDR-TB epidemic in the developing world.

3 Jun 2010

Illumina commences shipment of new HumanOmni2.5-Quad DNA Analysis BeadChip microarray

Illumina, Inc. today announced that it has begun shipping its new HumanOmni2.5-Quad DNA Analysis BeadChip (Omni2.5). This microarray contains millions of newly discovered genome-wide common and rare variants from the 1,000 Genomes Project (1kGP), selected to maximize its ability to detect new associations.

From Illumina, Inc. 2 Jun 2010

Hitachi Software, OriGene announce co-marketing agreement

Hitachi Software Engineering America, Ltd. and OriGene Technologies, Inc. today announced a co-marketing agreement to jointly promote OriGene's multiplex assays built on Luminex xMAP/Bio-Plex technology and Hitachi Software's MasterPlex software suite for analysis and reporting of multiplex assay data.

29 May 2010

Researchers discover genetic variant that raises risk of CHD

Although congenital heart disease represents the most common major birth defect, scientists have not previously identified the common variation in the genes that give rise to it. Now genetics and cardiology researchers, two of them brothers, have discovered a genetic variant on chromosome 5 that strongly raises the risk of congenital heart disease.

27 May 2010